Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Knapp

Geriatric Medicine Florissant, MO Doctor of Osteopathy

NPI 1023099140 CMS profile 45968

2137 Charbonier Rd Ste B, Florissant, MO 63031

Open in the dashboard

General payments

$4,535

251 records reported · program years 2019–2025

Research payments

$5,670

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$195,500 paid to institutions, not to them · program years 2019–2021

Through program year 2025, William Knapp of Florissant, MO is reported in the CMS Open Payments database as having received $4,535 across 251 general payments and $5,670 in research payments paid to them. Separately, studies naming them as principal investigator received $195,500 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,251 64
2024 General $832 33
2023 General $539 30
2022 General $445 26
2022 Research $5,670 1
2021 General $101 5
2020 General $490 31
2019 General $876 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Knapp
  • Geriatric Medicine median
  • Middle half of Geriatric Medicine
  • National median

In program year 2025, general payments to William Knapp were reported at $1,251. Among 512 Geriatric Medicine profiles paid that year, the median was $120 and the middle half received between $37 and $350.

Show as a table
Year William Knapp Geriatric Medicine median Middle half National median
2019 $876 $96 $28–$339 $163
2020 $490 $99 $28–$262 $114
2021 $101 $94 $27–$318 $132
2022 $445 $103 $34–$338 $149
2023 $539 $109 $39–$320 $160
2024 $832 $125 $36–$371 $164
2025 $1,251 $120 $37–$350 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,102 46 payments
  2. Lilly USA, LLC $559 29 payments
  3. GlaxoSmithKline, LLC. $527 38 payments
  4. AbbVie, Inc. $417 18 payments
  5. Novo Nordisk Inc $333 22 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $279 18 payments
  7. Pfizer Inc. $237 13 payments
  8. Amgen Inc. $173 9 payments
  9. Exact Sciences Corporation $100 6 payments
  10. Janssen Pharmaceuticals, Inc $95 7 payments
  11. Other $714 45 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,534 250 payments
  2. Education $1 1 payment
Products named General payments · program years 2019–2025
  1. FARXIGA $785 26 payments
  2. AIRSUPRA $660 17 payments
  3. TRELEGY ELLIPTA $396 28 payments
  4. Ozempic $307 20 payments
  5. BREZTRI $306 4 payments
  6. UBRELVY $292 12 payments
  7. TRULICITY $276 15 payments
  8. MOUNJARO $257 12 payments
  9. JARDIANCE $254 15 payments
  10. RYBELSUS $201 12 payments
  11. Other $3,021 183 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Applied Therapeutics, inc. $5,670 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 203 drugs

Part D claims

16,231

Median for Internal Medicine: 777

Drug cost

$1,167,526

Median for Internal Medicine: $73,373

Branded share of claims

20%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 142 $162,809
Jardiance Empagliflozin Brand 154 $158,126
Eliquis Apixaban Brand 173 $152,058
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 88 $71,899
Xarelto Rivaroxaban Brand 58 $70,947
Tradjenta Linagliptin Brand 52 $38,350
Semglee (Yfgn) Pen Insulin Glargine-Yfgn Brand 43 $29,846
Descovy Emtricitabine/Tenofov Alafenam Brand 11 $27,458
Entresto Sacubitril/Valsartan Brand 16 $25,122
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 21 $24,184

The 10 drugs with the highest cost, of 203 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 65 billing codes

Paid by Medicare

$38,540

Of which drugs: $3,703

Medicare patients

115

Average age 76

Services billed

1,688

54 women, 61 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 64%
Ischemic heart disease 33%
Chronic kidney disease 33%
Depression 31%
Atrial fibrillation 30%
Diabetes 29%
COPD 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 34 35 $2,739

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $144
$144 18 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $117
$117 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $99
$99 21 —
Ozempic
  • Novo Nordisk Inc $47
$47 142 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $36
  • Lilly USA, LLC $9
$44 154 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

252 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Medicine in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record